[Secondary amyloidosis (AA) and renal disease]. 2003

E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
Servicio de Nefrología Hospital General de Castellón Avda. de Benicassim, s/n. 12004 Castellón de la Plana.

Amyloidosis is a disease resulting from extracellular deposition of fibrillar protein in various organs. AA amyloidosis may complicate chronic inflammatory diseases, chronic infections and another chronic diseases. We review 31 patients (13 males and 18 females) with biopsy proven renal or rectal AA amyloidosis, referred to out hospital between january 1999 and november 2002. Renal failure was defined as serum creatinine > or = 1.5 mg/dl. Mean age was 58.4 +/- 15.7 years. The causes of AA amyloidosis were an underlying chronic rheumatologic disease (51.6%), chronic infection (41.9%) and a chronic inflammatory intestinal disorder (6.5%). Renal failure (RF) was detected in 20 patients (61.2%) and proteinuria and hematuria were found in 90.3% and 45.5 respectively. Proteinuria at diagnosis was 5.2 +/- 3.9 g/24 h and mean serum creatinine 3.5 +/- 3.7 mg/dl. Survival of patients without dialysis was 66.8 (51.1% RF, 90.9% non-RF) and 53.4% (38.2 RF, 77.9% non-RF) at 12 and 24 months respectively (p = 0.017). End-stage renal disease developed in 13 patients (41.9%). Ten patients were maintained on hemodialysis and 3 on CAD. Survival in dialysis at 6 and 12 months was 68.3% and 42.7% respectively. Fifteen patients died and the main causes of death were: infections (46.6) haemorrhagic complications (33.3%), cardiovascular events (13.3%) and cachexia (6.6%).

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007677 Kidney Function Tests Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine. Function Test, Kidney,Function Tests, Kidney,Kidney Function Test,Test, Kidney Function,Tests, Kidney Function
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000685 Serum Amyloid A Protein An ACUTE PHASE REACTION protein present in low concentrations in normal sera, but found at higher concentrations in sera of older persons and in patients with AMYLOIDOSIS. It is the circulating precusor of amyloid A protein, which is found deposited in AA type AMYLOID FIBRILS. Amyloid Protein SAA,Amyloid Serum Protein SAA,Serum A Related Protein,Amyloid A Precursor,Amyloid A Protein,Amyloid A Protein-Related Serum Component,Amyloid Fibril Protein AA,Amyloid Protein AA,Amyloid Protein AA Precursor,Amyloid-Related Serum Protein (SAA),Serum Amyloid A,Serum Amyloid Protein A,Amyloid A Protein Related Serum Component
D000686 Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. Amyloidoses

Related Publications

E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
October 2009, Clinical nephrology,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
January 2011, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
November 2018, Rheumatic diseases clinics of North America,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
January 1998, Ryoikibetsu shokogun shirizu,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
December 1992, Journal of internal medicine,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
September 2011, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
October 2014, Clinical kidney journal,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
April 2015, Medicina clinica,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
August 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
E Torregrosa, and J Hernández-Jaras, and C Calvo, and A Ríus, and H García-Pérez, and F Maduell, and J M Vera
January 2012, Renal failure,
Copied contents to your clipboard!